CbdMD's Clinical Study Supports Improved Mobility in Dogs

CbdMD's Clinical Study Supports Improved Mobility in Dogs - Pawsh Bandanas

To provide the most accurate assessment of the product's benefits in dogs, the clinical study relied upon several outcome measures including objective gait analysis and clinically supported owner surveys which provide a more realistic assessment of a dog's quality of life. The Canine Brief Pain Inventory (CBPI) utilizes a series of questions for the owner to determine how pain interferes with the dog's typical activities (pain interference scores) and pain severity (pain severity scores). The study was a placebo-controlled crossover design with the dogs receiving either a broad-spectrum hemp extract or a placebo daily for 45 days each.

Dogs in the group that consumed cbdMD's broad spectrum hemp extract showed a positive impact to most outcome measures, including improvements in the dogs' behavior scores and decreases in their pain scores, as compared to baseline measurements. There was also a trend for improvement in objective gait analysis and accelerometry (using devices attached to the body to measure accelerations), both objective measures which would not be affected by caregivers' perception. The data supports what we at cbdMD have known for some time: dogs with movement issues that take cbdMD's broad spectrum hemp extract show improvement. We will publish the final conclusions from this study later in 2023.

"At cbdMD, we believe that our furry friends' wellbeing is just as important as our human customers. We are committed to providing the same quality and efficacy products to our pets. These favorable outcomes will form the basis for future Paw CBD product formulations to meet pets' needs," said Dr. Sibyl Swift, cbdMD's Chief Science Officer.

"Osteoarthritis is a severely debilitating disease that affects pets and people alike. The cbdMD study adds further data to the current literature, suggesting that CBD may be a valuable addition to other forms of pain control for our canine patient," said Felix Duerr, principal investigator of the study and an assistant professor in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. "Our data also provide preliminary evidence that short-term co-administration with NSAIDs may be safe, which is exciting news for our canine patients. Further work with a larger sample size is needed to confirm our findings. We are grateful for cbdMD's continued support of this research."

See the detailed press release here.


Leave a comment

Please note, comments must be approved before they are published

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.